BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VTIMEZONE TZID:Europe/Vienna BEGIN:STANDARD DTSTART:20211031T020000 RDATE:20220327T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20221030T020000 RDATE:20230326T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20231029T020000 RDATE:20240331T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20241027T020000 RDATE:20250330T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20251026T020000 RDATE:20260329T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20261025T020000 RDATE:20270328T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20271031T020000 RDATE:20280326T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20281029T020000 RDATE:20290325T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20291028T020000 RDATE:20300331T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20301027T020000 RDATE:20310330T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20311026T020000 RDATE:20320328T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20321031T020000 RDATE:20330327T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20331030T020000 RDATE:20340326T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20341029T020000 RDATE:20350325T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:DAYLIGHT DTSTART:20210606T090000 RDATE:20211031T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20220327T030000 RDATE:20221030T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20230326T030000 RDATE:20231029T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20240331T030000 RDATE:20241027T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20250330T030000 RDATE:20251026T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20260329T030000 RDATE:20261025T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20270328T030000 RDATE:20271031T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20280326T030000 RDATE:20281029T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20290325T030000 RDATE:20291028T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20300331T030000 RDATE:20301027T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20310330T030000 RDATE:20311026T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20320328T030000 RDATE:20321031T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20330327T030000 RDATE:20331030T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20340326T030000 RDATE:20341029T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID: CATEGORIES:Symposium SUMMARY:What's new in immunotherapies 2022 LOCATION:London - UK DESCRIPTION;ENCODING=QUOTED-PRINTABLE:
Immunotherapy is a hot-topic
field of research that has generated significant scientific interest and fu
elled industrial innovation.
It has been demonstrated that sma
ll, drug-like molecules can be highly effective modulators of immune respon
se pathways and that their molecular properties can be fine-tuned to enable
excellent cell permeability and bioavailability. This makes them ideal for
use in the treatment of chronic conditions such as autoimmune and inflamma
tion-related diseases. Excitingly, this approach also offers the possibilit
y to treat cancer by harnessing the body’s own immune system to fight
tumours.
This meeting will offer a broad introduction to thos
e new to the topic and showcase recent innovations by academic and industri
al scientists in this exciting and rapidly expanding field.
An abstract of maximum one A4 pag e or 300 words indicating title and authors should be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.&n bsp;by Monday 31 January 2022 with the subject l ine “What's New in Immunotherapies - poster abstract submission&q uot;. Please use the template attached here.
The event is targeted at research students, researchers, academic and ind ustrial scientists engaged in all aspects of research into small molecule i mmunotherapy, and those interested in broadening their knowledge in this gr owing field.
This event is being held back to back with " Targeting protein degra dation 3 – from discovery to the clinic".
Confirmed speakers:
In vitro assays for immunotherapy drug discovery prog
rams; overview and emerging areas
Dr Rhoanne McPherson, Conc
ept Life Sciences &n
bsp;
Optimisation of Mer/Axl kinase inhibitors for imm
uno-oncology
Dr William McCoull, AstraZeneca
The discovery of BD2 selective BET inhibitors
Dr Emman
uel Demont, GlaxoSmithKline
First-in-class inhibitors
of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T ce
ll response leading to tumour growth inhibition
Dr Andrew Le
ishman, Grey Wolf therapeutics
Discovery and Development of
novel Small Molecule Inhibitors of IL-17
Dr Anne Foley, UCB<
/p>
Professor Edward Tate, Imperial College
Enabling natu
ral killer cell immunotherapy of cancer with small molecules
Professor Matthew J. Fuchter, Imperial College
CONTACT:SCI DTSTAMP:20240328T160432Z DTSTART;TZID=Europe/Vienna:20220607T090000 DTEND;TZID=Europe/Vienna:20220607T180000 SEQUENCE:1 TRANSP:OPAQUE END:VEVENT END:VCALENDAR